As of 2024-12-14, the Intrinsic Value of ACADIA Pharmaceuticals Inc (ACAD) is
10.46 USD. This Acadia valuation is based on the model Peter Lynch Fair Value.
With the current market price of 17.26 USD, the upside of ACADIA Pharmaceuticals Inc is
-39.40%.
10.46 USD
Intrinsic Value
Acadia Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(39.41) - (11.16) |
(17.38) |
-200.7% |
| DCF (Growth 10y) |
(14.14) - (46.64) |
(21.35) |
-223.7% |
| DCF (EBITDA 5y) |
(7.88) - (9.01) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(11.29) - (13.91) |
(1,234.50) |
-123450.0% |
| Fair Value |
10.46 - 10.46 |
10.46 |
-39.40% |
| P/E |
15.89 - 21.25 |
17.53 |
1.6% |
| EV/EBITDA |
13.71 - 19.95 |
14.76 |
-14.5% |
| EPV |
(9.43) - (13.28) |
(11.35) |
-165.8% |
| DDM - Stable |
5.09 - 19.49 |
12.29 |
-28.8% |
| DDM - Multi |
(3.02) - (9.40) |
(4.62) |
-126.8% |
Acadia Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
2,871.89 |
| Beta |
1.35 |
| Outstanding shares (mil) |
166.39 |
| Enterprise Value (mil) |
2,716.74 |
| Market risk premium |
4.60% |
| Cost of Equity |
11.09% |
| Cost of Debt |
5.00% |
| WACC |
8.03% |